Premium
Protection against aspirin‐induced gastric lesions by lansoprazole: Simultaneous evaluation of functional and morphologic responses
Author(s) -
Bergmann JeanFrançois,
Chassany Olivier,
Simoneau Guy,
Lemaire Marc,
Segrestaa JeanMarc,
Caulin Charles
Publication year - 1992
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1992.164
Subject(s) - lansoprazole , aspirin , medicine , placebo , proton pump inhibitor , gastric mucosa , gastroenterology , gastric acid , crossover study , pharmacology , stomach , helicobacter pylori , pathology , alternative medicine
The protective effect of lansoprazole, a new proton pump inhibitor, against aspirin‐induced gastric lesions was studied in a double‐blind crossover trial with a simultaneous measure of the functional capacities of the mucosal barrier (by a recording of the gastric potential difference) and of the morphologic changes in the mucosa (by gastric endoscopy). After 1 week of treatment with lansoprazole (30 mg per day) or placebo, each healthy volunteer received 1 gm aspirin by mouth. Recording of the gastric potential difference lasted for 3 hours and was followed by gastric endoscopy. Morphologic lesions induced by aspirin were effectively prevented by lansoprazole: Lanza score was 0.67 ± 0.98 (mean ± SD) versus 2.25 ± 1.1 with placebo (p < 0.005, ANOVA). Conversely, the decrease in the gastric potential difference was similar. The inhibition of acid secretion induced by lansoprazole was therefore sufficient to prevent aspirin‐induced mucosal lesions without reinforcing the defense capacities of the mucosa. This simple pharmacologie model makes it possible to simultaneously evaluate the functional and morphologic effects of aspirin intake on the gastric mucosa. Clinical Pharmacology and Therapeutics (1992) 52, 413–416; doi: 10.1038/clpt.1992.164